一种新开发的水飞蓟宾纳米制剂，作为实验性糖尿病的潜在抗糖尿病药物。
A newly developed silymarin nanoformulation as a potential antidiabetic agent in experimental diabetes.
机构信息
Department of Clinical Biochemistry, Faculty of Pharmacy, Mansoura University, 35516, Egypt.
Urology & Nephrology Center, Mansoura, 35516, Egypt.
出版信息
Nanomedicine (Lond). 2016 Oct;11(19):2581-602. doi: 10.2217/nnm-2016-0204. Epub 2016 Sep 13.
AIM
This study aimed to develop a new stable nanoformulation of silymarin (SM) with optimum enhanced oral bioavailability and to evaluate its effect as well as mechanism of action as a superior antidiabetic agent over native SM using streptozotocin-induced diabetic rats.
MATERIALS AND METHODS
SM-loaded pluronic nanomicelles (SMnp) were prepared and fully characterized. Biochemical parameters were performed as well as histological, confocal and reverse-transcription polymerase chain reaction studies on pancreatic target tissues.
RESULTS & CONCLUSION: SMnp were found to improve significantly the antihyperglycemic, antioxidant and antihyperlipidemic properties as compared with native SM. In addition, SMnp was found to be a more efficient agent over SM in the management of diabetes and its associated complications due to its superior bioavailability in vivo, and the controlled release profile of SM. [Formula: see text].
目的
本研究旨在开发一种新型稳定的水飞蓟宾（SM）纳米制剂，以最大限度地提高其口服生物利用度，并通过链脲佐菌素诱导的糖尿病大鼠模型，评估其作为一种优于天然 SM 的优越抗糖尿病药物的作用机制。
材料和方法
制备并全面表征载有水飞蓟宾的泊洛沙姆纳米胶束（SMnp）。对胰腺靶组织进行生化参数以及组织学、共聚焦和逆转录聚合酶链反应研究。
结果与结论
与天然 SM 相比，SMnp 显著改善了降血糖、抗氧化和降血脂特性。此外，由于其在体内具有更高的生物利用度和 SM 的控释特性，SMnp 在糖尿病及其相关并发症的治疗中比 SM 更有效。
Zotero 插件